UBS Maintains Positive Outlook on AstraZeneca Ahead of Q2 Earnings

UBS has reiterated its 'buy' rating for AstraZeneca ahead of its second-quarter results, scheduled for July 27. The bank expects strong performance but sees limited scope for the company to raise full-year guidance.

By Proactive Mon, July 13, 2026 at 2:31 PM GMT+3 2 min read · Yahoo Finance · July 13, 2026, 11:31 UTC

UBS Maintains Positive Outlook on AstraZeneca Ahead of Q2 Earnings

Tickers: $AZN

Topics: AstraZeneca drug trials earnings guidance UBS

Read the full article at Yahoo Finance

More World news

PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC